Biomedical Catalyst - Early Stage Awards

Objectives and Scope

The aim of the Biomedical Catalyst is to support the development of innovative healthcare products, technologies and processes. Support is available for any sector or discipline, including but not limited to:

  • stratified healthcare;
  • advanced therapies (gene and cell therapies);
  • diagnostics;
  • medical technologies and devices.

The aim of the early stage award is to create a data package that is sufficient to support the subsequent testing of products or process in a clinical setting or other relevant environment. It can include:

  • experimental evaluation (at laboratory scale);
  • use of in vitro and in vivo models to evaluate proof of concept or safety;
  • exploring potential production mechanisms;
  • early stage prototyping;
  • product development planning;
  • intellectual property protection.

Eligibility and Funding

Only UK organisations are eligible to participate. All projects must be led by a UK based SME.  

The total funding allocated for early stage awards is £8m. Project costs of between £200k to £1.5m are expected for projects with durations of up to 2 years.

Successful applicants can receive funding:

  • up to 70% of your eligible project costs if you are a micro/small business;
  • up to 60% if you are a medium-sized businesses.

Large organisations are not eligible for funding.

Research organisation funding is capped at 50% of total eligible project costs, which is to be shared between such organisations if more than one participates.

Key Dates

Competition launch: 26/03/2018

Application deadline: 06/06/2018

Interviews: 01-02/10/2018

Notification of decisions: 31/10/2018

Ask clarifications to our BIOPEN expert in Horizon2020 and in National and European funding programs